Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy
- PMID: 15347714
Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy
Abstract
We evaluated quantitative measurement series (MS) with 18F-FDG and PET and compared different quantification methods for prediction of individual survival in patients with metastatic colorectal cancer receiving chemotherapy with 5-fluorouracil, folinic acid, and oxaliplatin (FOLFOX).
Methods: The study comprised 25 patients. All patients were examined before the onset of FOLFOX therapy and after completion of the first and fourth cycles. SUV, fractal dimension (FD), a 2-compartment model with computation of k1, k2, k3, and k4, and vascular fraction (VB) were used for data evaluation. Survival data served as a reference for the PET data. Discriminant analysis (DA), regression, and best-subset analysis were applied to the data.
Results: Twenty of 25 patients died up to 801 d after the first PET study. A cutoff of 1 y (364 d) was used to classify the patients into 2 a priori groups, namely the short- and long-term survival groups. DA was used to predict the 2 categories using SUV and kinetic parameters of 18F-FDG metabolism as predictor variables. SUV provided a correct classification rate (CCR) ranging from 62% to 69%. SUV of the third MS resulted in a CCR of 69% as a single parameter. The best results were yielded by the use of kinetic parameters (k1, k3, VB, and FD) as predictor variables. CCR was 78% using kinetic 18F-FDG parameters of the first and third MS, in comparison with 69% for the corresponding SUVs. A multiple linear regression model was applied to the data to assess the relationship between individual survival and the PET data. The best-subset method revealed a correlation coefficient of 0.850 for the kinetic parameters of the first (k3, k4, VB, and FD) and third (k1, k2, k4, and VB) MS.
Conclusion: The combination of kinetic parameters of the first and the third MS is acceptable for classification into a short or long survival class. Furthermore, even an individual prognosis of survival can be achieved using kinetic 18F-FDG parameters of the first and third MS.
Comment in
-
18F-FDG PET in evaluating patients treated for metastatic colorectal cancer: can we predict prognosis?J Nucl Med. 2004 Sep;45(9):1428-30. J Nucl Med. 2004. PMID: 15347706 No abstract available.
Similar articles
-
PET-FDG as predictor of therapy response in patients with colorectal carcinoma.Q J Nucl Med. 2003 Mar;47(1):8-13. Q J Nucl Med. 2003. PMID: 12714949 Clinical Trial.
-
Prediction of progression-free survival in patients with multiple myeloma following anthracycline-based chemotherapy based on dynamic FDG-PET.Clin Nucl Med. 2009 Sep;34(9):576-84. doi: 10.1097/RLU.0b013e3181b06bc5. Clin Nucl Med. 2009. PMID: 19692817 Clinical Trial.
-
Quantitative, dynamic 18F-FDG-PET for the evaluation of soft tissue sarcomas: relation to differential diagnosis, tumor grading and prediction of prognosis.Hell J Nucl Med. 2009 Sep-Dec;12(3):223-8. Hell J Nucl Med. 2009. PMID: 19936332
-
Chemotherapy of metastatic colorectal cancer.Prescrire Int. 2010 Oct;19(109):219-24. Prescrire Int. 2010. PMID: 21180382 Review.
-
Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Pro: The CapeOx regimen is preferred over FOLFOX.Clin Adv Hematol Oncol. 2005 May;3(5):400-4. Clin Adv Hematol Oncol. 2005. PMID: 16167013 Review. No abstract available.
Cited by
-
Correlation of GLUT-1 overexpression, tumor size, and depth of invasion with 18F-2-fluoro-2-deoxy-D-glucose uptake by positron emission tomography in colorectal cancer.Dig Dis Sci. 2006 Dec;51(12):2198-205. doi: 10.1007/s10620-006-9428-2. Epub 2006 Nov 2. Dig Dis Sci. 2006. PMID: 17080242
-
Early effects of FOLFOX treatment of colorectal tumour in an animal model: assessment of changes in gene expression and FDG kinetics.Eur J Nucl Med Mol Imaging. 2009 Aug;36(8):1226-34. doi: 10.1007/s00259-009-1102-4. Epub 2009 Mar 11. Eur J Nucl Med Mol Imaging. 2009. PMID: 19280186
-
Abbreviated scan protocols to capture 18F-FDG kinetics for long axial FOV PET scanners.Eur J Nucl Med Mol Imaging. 2022 Jul;49(9):3215-3225. doi: 10.1007/s00259-022-05747-3. Epub 2022 Mar 12. Eur J Nucl Med Mol Imaging. 2022. PMID: 35278108 Free PMC article.
-
FDG-PET in colorectal cancer.Cancer Imaging. 2006 Oct 31;6(Spec No A):S71-81. doi: 10.1102/1470-7330.2006.9014. Cancer Imaging. 2006. PMID: 17114081 Free PMC article.
-
DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6.Br J Cancer. 2011 Jun 28;105(1):139-45. doi: 10.1038/bjc.2011.191. Epub 2011 Jun 14. Br J Cancer. 2011. PMID: 21673686 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical